γδ T Cells in Cancer Immunotherapy, 2000-2025: A Bibliometric Analysis and Clinical-Trial Evidence Map.
γδ T cells are promising cancer-immunotherapy effectors because they recognize tumors without major histocompatibility complex (MHC) restriction and carry low graft-versus-host-disease risk in allogeneic settings, yet few bibliometric studies have integrated immunotherapy-specific research trends with clinical-trial ma...